- Home
- KELYB vs SLN Comparison
KELYB vs SLN Comparison
Compare KELYB & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KELYB
- SLN
- Stock Information
- Founded
- KELYB 1946
- SLN 1994
- Country
- KELYB United States
- SLN United Kingdom
- Employees
- KELYB N/A
- SLN N/A
- Industry
- KELYB Professional Services
- SLN Biotechnology: Pharmaceutical Preparations
- Sector
- KELYB Consumer Discretionary
- SLN Health Care
- Exchange
- KELYB Nasdaq
- SLN Nasdaq
- Market Cap
- KELYB 389.9M
- SLN 345.3M
- IPO Year
- KELYB N/A
- SLN N/A
- Fundamental
- Price
- KELYB $11.06
- SLN $6.24
- Analyst Decision
- KELYB
- SLN Buy
- Analyst Count
- KELYB 0
- SLN 6
- Target Price
- KELYB N/A
- SLN $39.67
- AVG Volume (30 Days)
- KELYB 201.0
- SLN 213.8K
- Earning Date
- KELYB 11-06-2025
- SLN 11-07-2025
- Dividend Yield
- KELYB 2.55%
- SLN N/A
- EPS Growth
- KELYB N/A
- SLN N/A
- EPS
- KELYB N/A
- SLN N/A
- Revenue
- KELYB $4,495,900,000.00
- SLN $27,169,000.00
- Revenue This Year
- KELYB $4.55
- SLN N/A
- Revenue Next Year
- KELYB $5.01
- SLN N/A
- P/E Ratio
- KELYB N/A
- SLN N/A
- Revenue Growth
- KELYB 0.97
- SLN 22.28
- 52 Week Low
- KELYB $11.04
- SLN $1.97
- 52 Week High
- KELYB $19.82
- SLN $18.24
- Technical
- Relative Strength Index (RSI)
- KELYB 36.66
- SLN 46.82
- Support Level
- KELYB $12.96
- SLN $7.06
- Resistance Level
- KELYB $13.47
- SLN $7.39
- Average True Range (ATR)
- KELYB 0.04
- SLN 0.58
- MACD
- KELYB -0.34
- SLN -0.12
- Stochastic Oscillator
- KELYB 0.00
- SLN 21.87
About KELYB Kelly Services Inc. Class B
Kelly Services Inc is a provider of workforce solutions and consulting, and staffing services. The company's operations are divided into four business segments, namely Professional & Industrial, Science, Education, Outsourcing & Consulting Group, and International. Other than OCG, each segment delivers talent through staffing services, permanent placement, or outcome-based services. OCG segment delivers talent solutions, including managed service providers, payroll process outsourcing, recruitment process outsourcing, and talent advisory services. International also delivers RPO talent solutions within its local markets. The majority of revenue is derived from Professional & Industrial.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.